Balaxi Pharmaceuticals (BALAXI) Q3 2025 earnings summary

Executive summary

• Achieved recovery in Angola and growth in Honduras and El Salvador, despite challenges in Dominican Republic and Guatemala.

• Board approved unaudited standalone and consolidated financial results for Q3 and nine months ended 31.12.2024.

• Secured 17 new product registrations in Q3 FY25, expanding the portfolio to 897 registered products across seven countries.

• Construction of the first manufacturing unit in Hyderabad is at an advanced stage, with commissioning scheduled for May 2025.

• Remuneration for Managing Director Ashish Maheshwari approved for tenure extension, pending shareholder approval.

Financial highlights

• Q3 FY25 consolidated revenue rose 20.6% year-over-year to INR 73.29 crore; net profit increased to INR 5.36 crore.

• Q3 FY25 EBITDA before exceptional items fell 41.4% year-over-year to INR 7.93 crore; EBITDA margin dropped to 10.81%.

• FY24 revenue declined 28.3% year-over-year to INR 241.29 crore; gross margin improved to 46.7%.

• FY24 EBITDA dropped 90% year-over-year to INR 5.79 crore; reported a net loss of INR 2.39 crore due to currency loss in Angola.

• Basic EPS (Q3 consolidated): Rs. 0.97; nine months: Rs. 2.66.

Outlook and guidance

• Manufacturing facility in Hyderabad expected to be operational by May 2025, enabling backward integration and improved supply chain efficiency.

• Focus remains on expanding product registrations and capturing market share in existing and new geographies.

• Board and auditors confirm compliance with Indian Accounting Standards and SEBI regulations.